Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Disease-Free Survival. Found 99 abstracts

no pagination
Bradshaw AW, Autorino R, Simone G, Yang B, Uzzo RG, Porpiglia F, Capitanio U, Porter J, Bertolo R, Minervini A, Lau C, Jacobsohn K, Ashrafi A, Eun D, Mottrie A, White WM, Schips L, Challacombe BJ, De Cobelli O, Mir CM, Veccia A, Larcher A, Kutikov A, Aron M, Dasgupta P, Montorsi F, Gill IS, Sundaram CP, Kaouk J, Derweesh IH. Robotic Partial Nephrectomy versus Minimally Invasive Radical Nephrectomy for Clinical T2a Renal Mass: A Propensity Score Matched Comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group. BJU international. 2020 Mar 31;.
Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MA, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. J Urol. 2020 Apr;203(4):684-9.
Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2020 Apr;203(4):690-8.
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DP, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England journal of medicine. 2018 Feb 22;378(8):731-9.   PMCID: PMC5857389
Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2018 Apr 05;378(14):1277-90.   PMCID: PMC5972549
Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD. Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. European urology focus. 2018 Dec;4(6):937-45.   PMCID: PMC5626651
Shaikh T, Wang LS, Egleston B, Burki M, Hoffman JP, Cohen SJ, Meyer JE. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol. 2018 Jan;41(1):59-64.   PMCID: PMC4769977
von Mehren M, Joensuu H. Gastrointestinal Stromal Tumors. J Clin Oncol. 2018 Jan 10;36(2):136-43.   PMCID: PMC6553810
Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Nov;18(11):1483-92.
Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol. 2017 Aug;40(4):393-8.   PMCID: PMC5026539
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJ, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA, CheckMate I. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. The New England journal of medicine. 2017 Jun 22;376(25):2415-26.   PMCID: Comment
Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DY, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. J Clin Oncol. 2017 Sep 10;35(26):2993-3001.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):779-91.   PMCID: PMC5715461
Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE. Phase III Randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non-small-cell lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (Alliance). Journal of Clinical Oncology. 2017 Jul;35(19):2184-92.   PMCID: PMC5493050
Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM, Barrett WL, Thorstad WL, Jones CU, Yom SS, Wong SJ, Ridge JA, Rao SS, Bonner JA, Vigneault E, Raben D, Kudrimoti MR, Harris J, Le QT, Gillison ML. Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. J Clin Oncol. 2017 Dec 20;35(36):4057-65.   PMCID: PMC5736236
Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters M, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DS, Wang HJ, Elashoff DA, Elashoff RM. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. The New England journal of medicine. 2017 Jun 08;376(23):2211-22.   PMCID: PMC5548388
Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol. 2017 Sep;3(9):1249-52.   PMCID: PMC5591751
Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Jul;123(13):2489-96.   PMCID: PMC5474197
Kantarjian HM, Roboz GJ, Kropf PL, Yee KW, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 Oct;18(10):1317-26.   PMCID: PMC5925750
Lawton CA, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M, Kwok Y, Dignam JJ, Sandler HM. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Jun;98(2):296-303.   PMCID: PMC5603177
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Disease-Free Survival

Disease-Free Survival Middle Aged Aged therapeutic use Male Adult pathology Female drug therapy adverse effects mortality administration & dosage Neoplasm Staging 80 and over Aged therapy Prognosis surgery methods Antineoplastic Combined Chemotherapy Protocols Antineoplastic Agents Survival Rate Kidney Neoplasms Survival Analysis Drug Administration Schedule Young Adult Treatment Outcome Neoplasm Invasiveness Prospective Studies metabolism Kaplan-Meier Estimate Proportional Hazards Models Renal Cell Carcinoma Local Neoplasm Recurrence genetics Risk Assessment Adenocarcinoma Transitional Cell Carcinoma diagnosis Carboplatin Adjuvant Chemotherapy analogs & derivatives Follow-Up Studies Drug Dose-Response Relationship Neoadjuvant Therapy Prostate-Specific Antigen Indoles Patient Safety Retrospective Studies Lymph Nodes statistics & numerical data Double-Blind Method Pyrroles Cohort Studies Randomized Controlled Trials as Topic Multivariate Analysis Lymph Node Excision antagonists & inhibitors blood Paclitaxel Maximum Tolerated Dose Neoplasm Grading Intravenous Infusions Prostatic Neoplasms enzymology secondary etiology Intensity-Modulated Radiotherapy Chemoradiotherapy Predictive Value of Tests Lung Neoplasms diagnostic imaging carcinoma Androgen Antagonists Cisplatin Phenylurea Compounds Tosyl Compounds Remission Induction Flutamide Lymphedema Adjuvant Chemoradiotherapy Preschool Child Fallopian Tube Neoplasms Infant Carcinoma Non-Small-Cell Lung Carcinoma Renal Cell Pancreatic Neoplasms Taxoids Incidence Prostatectomy Piperidines Tumor Biomarkers urinary tract Dinoprostone Anilides postprostatectomy chemotherapy Urothelium Sentinel Lymph Node Celecoxib biosynthesis Robot-assisted surgery drug effects Myeloid Leukemia-Acute adverse Ureteral Neoplasms physiopathology local Oral Administration Bevacizumab Phase III Clinical Trials as Topic Urinary Bladder Neoplasms effects Quinazolines Gastrointestinal Stromal Tumors Smooth Muscle Nomograms Adolescent Fluorouracil Neoplasm Drug Resistance Robotic-Assisted Partial Nephrectomy Internationality Muscle-invasive disease Pemetrexed Protein Kinase Inhibitors Margins of Excision androgen deprivation Cytoreduction Surgical Procedures Sorafenib Gonadotropin-Releasing Hormone radiotherapy Postoperative Complications urothelium Watchful Waiting docetaxel Pyrazoles Nephrectomy chemically induced Hematologic Diseases urine Ipilimumab Quality of Life Goserelin CD274 Antigens Squamous Cell Carcinoma Risk Factors Molecular Targeted Therapy Monoclonal Antibodies-Humanized Gastrointestinal Neoplasms chemistry
Last updated on Saturday, July 04, 2020